Novartis launches Neupogen copycat Zarxio in U.S. market
September 03, 2015 at 01:30 AM EDT
ZURICH, Sept 3 (Reuters) - Novartis AG has launched the first biosimilar drug in the United States after a U.S. appeals court declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
